The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
On a quarterly basis, companies in areas like cell and gene therapy raised less in the second quarter than during the same period last year, but the number of clinical trials underway saw an uptick. European and Israeli firms also saw a boost in funding.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
At the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day in New York Thursday, industry insiders gathered to talk about CAR-Ts in solid tumor cancers.
Panelists discussed the outlook for cell and gene therapy investing at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day in New York Thursday.
Hospitals - especially in Europe - anticipate growing interest from international patients. But a wave of industry consolidation is debatable.
From bringing in a mere 350 scientists in an embattled field 12 years ago, this year's Alliance for Regenerative Medicine Cell and Gene Meeting brought in more than 1,200.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.